Ascletis Pharma Inc. (Ascletis) reported in its 14 July 2026 Next Day Disclosure Return that it purchased 200,000 ordinary shares on-market the same day at prices ranging between HK$10.19 and HK$11.31 per share, for an average cost of HK$10.45 per share. The aggregate consideration was approximately HK$2.09 million.

These shares are designated for cancellation and raise the total volume repurchased under the shareholder mandate granted on 29 June 2026 to 545,000 shares, equivalent to 0.05 % of Ascletis’s issued share capital (excluding treasury shares) on the mandate date. The company is authorised to buy back up to 106.14 million shares; thus, around 99.6 % of the current mandate capacity remains.

As of 14 July 2026, Ascletis’s outstanding share capital stood unchanged at 1,061.37 million shares (excluding treasury shares), while treasury shares totalled 7.08 million. Cumulatively, 9.93 million shares had been repurchased for cancellation but were not yet cancelled as of the reporting date—equivalent to roughly 0.94 % of the issued share base.

In accordance with Hong Kong Stock Exchange rules, Ascletis is subject to a moratorium on issuing new shares or selling any treasury shares until 13 August 2026.